Buy UltraTech Cement on dips: Anu Jain

Anuj Jain, Director – Equities at IIFL Private Wealth Management told CNBC-TV18, " UltraTech Cement  , given the way it closed on Friday, it gave up most of the steam, it is good to pick up closer to Rs 3000 or Rs 2990. It is poised towards Rs 3300. So, it is a buy on dips. On Friday it gave up, so there is a possibility of a couple of percentages down before it moves up." " India Cements on the other hand has kept the steam on Friday. 

There is some minor resistance closer to Rs 105 and it can actually move upto Rs 112-113. So, there is momentum still in it. The smaller ones will also start, so, JK Lakshmi Cement has stated to show some accumulation," she added.

Buy Gateway Distriparks on dips: Anu Jain

Anuj Jain, Director – Equities at IIFL Private Wealth Management told CNBC-TV18, "There are certain stocks which kind of stood out on the basis of which they were accumulated.  Gateway Distriparks  , despite the way it has moved up, even at the current level of Rs 365, any dips or up to Rs 355 one can look at picking up this stock. For a medium term, the target is as high as about Rs 400-420. In the mid term if one is playing for about 15-20 days, around Rs 375-385 is what one should get which is still about 7-8 percent move which is still left into the counter." "We have seen a big move coming along with banking into infra. 

So, there was a lot of short covering and a move up there. So, there are signals both in Sadbhav Engineering , Blue Star  and in Voltas  but I would like to give Blue Star as a call. In the medium term again like Gateway Distriparks the targets are very high of about Rs 425. So, for somebody who is looking at as an investment call also, we are advising this," she said. "For a safe person who does not want to play any of these, there is probably Glenmark Pharma . Looking for a target of Rs 750 and stoploss of about Rs 705."

Short Hero Motocorp, says Amit Harchekar

Amit Harchekar of A Plus Analytics told CNBC-TV18, " Hero Motocorp  is continuously forming lower-top and lower-bottom formation. Even despite yesterday’s smart pullback in the market, the stock was unable to close with the gains of more than 2 percent and that is the major sign of concern. It has already breached the long-term support line below Rs 3,150 and now the stock is projecting a target close to Rs 2,700 in the near term.

Any pullback towards Rs 3,000 becomes a good selling opportunity, in fact if anyone is initiating short positions at current level one can go short with the stoploss of Rs 3,050 and target can be seen at around Rs 2,750, he added.

Go long in Bharat Electronics, says Amit Harchekar

Amit Harchekar of A Plus Analytics told CNBC-TV18, "On monthly chart Bharat Electronics   has given another breakout above Rs 3,250 andthat transforms into a price target somewhere around Rs 3,650-3,700 on 15-20 days perspective. In the short-term, good buying is seen in the zone of Rs 3,250-3,300. So this becomes good accumulation zone.

From a technically perspective one can go long in this stock at current level with a stoploss of Rs 3,200 and we are expecting this stock to test level of Rs 3,450-3,600 in the next coming days, he added.

Buy Aditya Birla Nuvo, says Kunal Bothra

Kunal Bothra, head of advisory at LKP told CNBC-TV18, "I have avoided the banking stocks particularly because of the kind of short-term resistance we are facing but from the midcap space, Aditya Birla Nuvo   seems to be a good stock. 

It is trading above its short-term moving averages . Looking at the fresh swing high being made this could be a good opportunity to buy Aditya Birla Nuvo.One could probably look at a target of Rs 60-70 further from the current price. So it could probably take it very close to Rs 1,825-1,850 and a stoploss placed at Rs 1,730," he said.

Hold Axis Bank, says Gaurang Shah

Gaurang Shah, VP at Geojit BNP Paribas Financial Services told CNBC-TV18, "We do have a positive coverage on  Axis Bank  and we have to factor in today’s number that the bank came out with and according to us, the estimates that we had lined up, the numbers were a tad better than what our expectation was. 

Our initial targets stand at about Rs 580, post these numbers there is credible data to say that we could possibly revise it upwards to about Rs 630." "If you are a long-term investor with the rate cuts heading top-down and incremental improvement on the economic front, I think the corporate loan book and retail loan book is likely to grow at a much more faster pace and given the kind of performance in the numbers, I think the coming quarters could only improve the visibility and the growth. So I would say hold on to it. 

As of now we are working with a target of Rs 580 but like I said, factoring today’s number, we would revise it upward but Rs 630 could be the possible target in year’s time," he added.

Stay invested in SBI: Gaurang Shah

Gaurang Shah, VP at Geojit BNP Paribas Financial Services told CNBC-TV18, " State Bank of India  (SBI) is one of the banks that is under our positive coverage in the banking universe from the public sector undertaking (PSU) banking lot. 

With top-down scenario for interest rate cut, the only issue has been with PSU bank is the asset quality and the restructuring/provisioning issues but given the fact that it is the largest public sector banks and with the recent initiatives by the government this bank also would tend to get benefited." "My advise to the investors would be to hold on to it, wait out for the numbers that will be seeing in maybe about a week or fortnight from State Bank of India (SBI). 

From the near-term we are working with a target of about Rs 345 and if numbers are something soothing and asset quality does not disappoint and of course the NIMs improve, definitely we would revise it upwards, so hold as of now," he added.

Buy M&M Financial; target of Rs 395: ICICIdirect

With the upcoming budget and result season, stock specific moves are likely to be seen in the market. M&M Finance, being into commercial vehicle lending, is one of the cheapest stocks available among its peers. Hence, it is likely to witness money flows in the days to come as sentiments improve further. Moreover, M&M Financial has almost recovered towards its November highs while broader index is still almost 200 points lower than those levels. 

It indicates ongoing buying momentum in the stock and it provides a good opportunity to ride further up move towards 400 levels. After making highs near Rs 340, M&M Financial witnessed significant addition of short positions. 

As a result, the stock declined sharply towards Rs 270 in the later part of December series. Since then as the stock recovered, closure of short positions is still continued and it has shed close to 30% open interest since the month of December. We expect the current short covering trend may scale up to Rs 400 levels in the near term.

Short Hindalco Industries; target of Rs 140: Emkay

The stock traded close to its strong resistance levels of 161 last Friday on back of lower delivery volumes. Delivery volume stood at 0.94 million shares (lowest in the current series) as against series average of 2.03 million shares. Lower than average delivery volumes at resistance levels indicate lower probability of any sustained breakout. % delivery volume on last Friday stood at 29.13%, lowest in the current series. 

Despite the up move from a low of 150 levels to a high of 160 levels in the current series, no significant accumulation of open interest has been observed. On the contrary, closure of positions was observed as open interest declined to 26 million shares from a high of 26.94 million shares. Cost of carry too has been on a declining trend. 

Dollar index has been gaining strength. Historical studies indicate the index has a maximum inverse correlation with the metal stocks. With further strength expected to continue to prevail in the dollar index, we believe the stock could see renewed selling pressure. 

Strategy "Accumulate short positions in Hindalco in the range of Rs 160-161 levels for an immediate target of Rs 140 levels. We recommend holding positions with a stop loss placed at Rs 170 levels on a closing basis.

Buy Divis Labs; target of Rs 2050: ICICIdirect

"Divis Lab has remained near Rs 1700 levels since the last couple of months. The traders who tried to go short in the stock are slowly exiting from their positions as the stock is reverting after remaining sideways for sometime. The stock also absorbed the recent losses in Nifty when the index fell from 8630 to 7970. 

During this period Divis Lab fell only from Rs 1680 to Rs 1640. It shows inherent strength in the stock and it is likely to move up as the index has finally shown signs of revival." "The current OI in the stock is one of the lowest seen in the last 3 months. Since the October expiry, the stock has remained subdued after hitting Rs 1875 levels. Initially there was long liquidation as open interest witnessed closure of over 7%. 

Post this closure, there was short addition of over 35% in a span of 2 trading sessions in the price range of Rs 1800-1840. Later the stock fell till Rs 1650-1700 and stuck up in this range since the month of November.

Buy Divis Lab in the range of Rs 1710-1735, target price: Rs 2050, stop loss: Rs 1556", says ICICIdirect.com research report.

Buy Everest Industries; target of Rs 378: ICICIdirect

"The share price of Everest industries looks ripe for next up move after five weeks of consolidation above its 2010 and 2013 peaks (Rs 267) and therefore offers fresh entry opportunity. Technically the robust price structure is clearly exhibited as stock price consolidated in a narrow range wherein it retraced its preceding up leg (242-321) only by 50% while consuming equal time taken for rally (5 weeks). 

Such price/time behaviour signals constant appetite to own the stock at higher levels." "Earlier share price broke past its multi year highs during November 2014 pointing towards major shift in long term price structure thereby lifting the stock price in higher orbit. We expect stock price to head towards 380 being the 123.6% extension of preceding up leg (242-321) as projected from December 2014 lows of Rs 280." "On the volume front it has been double its 50 week average ~ 1.5 lakh shares during rallies which boost longevity of up trend. The rising MACD which is firmly placed in positive territory supports overall bullish momentum in the stock.

Buy Everest Industries in the range of Rs 317.00-323.00 for a target of Rs 378.00 with a stop loss below Rs 295.00 on a closing basis", says ICICIdirect.com research report.

Buy Gujarat Pipavav; target of Rs 221: ICICIdirect

"Gujarat Pipavav Port (GPPL) has entered into an arrangement with NYK Auto Logistics (India) Pvt Ltd (NYK) where NYK has sub-leased land for developing a dedicated common user integrated roll-in roll-out (RO-RO) yard at Pipavav Port. The RO-RO yard has annual designed capacity to handle 250,000 vehicles and is expected to be operational in the first quarter of CY15. This is another effort on part of GPPL to diversify its cargo base, thereby insulating itself from a downturn in any particular segment. Earlier this year, GPPL commenced its new business line of handling liquid cargo (handled nearly 96,695 MT in Q3CY14). 

This is further expected to ramp up as new capacity gets added and the existing stabilises. The container volume for GPPL has shown strong growth of ~25% YoY due to addition of new services over the years and upgradation of existing clients; also, going ahead we anticipate container volume to post CAGR of ~17% over CY13-16E. However, any new line of business is expected to smoothen out the volatility of revenue growth." "With the addition of a couple of new business lines and improved revenue visibility, GPPL is expected to post a revenue CAGR of nearly 20% over CY11-15 whereas EBITDA CAGR is anticipated at ~27% over the same period. As nearly 70% of GPPL’s cost is fixed, the new business is expected to further improve the operating leverage, thereby aiding the EBITDA margin. 

Further, GPPL’s debt free structure and ECB funding for new capex is expected to bring down the interest cost. A diversified cargo portfolio and presence in high growth segments like tank farms and auto export provide confidence on the earnings growth of GPPL.

 Consequently, we revise our estimates upwards and have a BUY recommendation on the stock with a DCF based target price of Rs 221", says ICICIdirect.com research report.

Accumulate Yes Bank; target Rs 855: KRChoksey

"Yes Bank reported a strong performance during the quarter with a PAT of Rs 540 crs (up 30.0% Y-o-Y & 12.0% Q-o-Q). 1) Net interest income grew strongly 36.6% Y-o-Y & 6.1% Q-o-Q on the back of a strong loan book growth of 32.4% Y-o-Y and stable NIMs sequentially 2) 

Following suite, non-interest has showed strong growth momentum up 38.4% Y-o-Y and 6.2% Q-o-Q on the back of third party distribution (+64.9% y/y), income from financial markets (+41.3% y/y) and financial advisory fees (42.8% y/y) 3) Operating expenses increased 32.9% Y-o-Y on the back of branch expansion 4) Provisions stood at Rs 70 crs in Q3FY15, a decline of 41.5% Q-o-Q 5) Asset quality has deteriorated during the quarter with 25.3% sequential increase in gross NPAs. 

Gross NPAs and Net NPAs stood at 0.4% & 0.1% respectively with PCR of 76.8% (up 108bps Q/Q) 6) Loan book grew 32.4% Y-o-Y & 7.4% Q-o-Q driven by a strong retail loan book (up 17.5% Q/Q) as wholesale lending softened 7) Deposits growth came at 21.0% Y-o-Y & 2.8% Q-o-Q, CASA ratio showed uptick 13bps Q-o-Q led by a healthy trajectory in saving deposits (up 42.8% Y-o-Y)." "The Bank has been delivering steady operating performance in the last few quarters. 

The bank’s valuation has re-rated on the back of falling wholesale rates, sturdy margins and built-up of a strong non-interest income profile. We believe further re-rating in the stock will be contingent on strong execution of retail strategy and NIM led expansion in ROA. We expect Yes Bank to deliver 24.6% CAGR in net profits over FY14-FY17. At Rs 787, the stock is trading at 2.4x FY16 adjusted book and 12.7x FY16 earnings, leaving limited upside from the current level. 

We maintain “ACCUMULATE” rating on the stock with target price of Rs 855, potential upside 8.6%", says KRChoksey research report.

Buy Corporation Bank; target Rs 365: Pritesh Mehta

Pritesh Mehta, Senior Technical Analyst at IIFL told CNBC-TV18, " Corporation Bank  has not participated for the last couple of months now. On the daily chart the stock has given a breakout from inverted head and shoulder pattern also this breakout has taken place after two months of consolidation and on the weekly chart the stock has given a breakout from a downwards slope trend line. There are back to back breakouts on the short-term and the medium-term charts.

 So buy Corporation bank for the target of Rs 365.' At 15:04 hrs Corporation Bank was quoting at Rs 339.05, up Rs 13.05, or 4.00 percent on the BSE. The share touched its 52-week high Rs 417.50 and 52-week low Rs 220.10 on 09 June, 2014 and 24 February, 2014, respectively.

Buy Sun Pharmaceutical Industries: Pritesh Mehta

Pritesh Mehta, Senior Technical Analyst at IIFL told CNBC-TV18, "It is not an opportunity to buy  Sun Pharmaceutical Industries  for short-term trading, but someone is willing to put money for at least couple of weeks, it could turnout be an ideal trade because we are talking about a stock which is available at reasonable price. In fact this stock is one of my favourite and it has gone through a bit of correction. This counter is up trending in nature, so every correction, every decline has to be brought into.

After the phase of correction the stock was into a period of consolidation for the month of December. Now on the daily chart, the stock is on the verge of breaking out from a rounding bottom pattern. So it tells us that the correction phase is over. So buy this stock," he said. 

Disclosure: Analyst might have recommended above trading idea to his clients, but no personal holdings.

Buy Tech Mahindra; target of Rs 3050: P Lilladher

"Tech Mahindra (TechM) has signed a definitive agreement to acquire SOFGEN Holdings Limited (SOFGEN). The transaction is expected to close by March 2015, subject to regulatory approvals. SOFGEN is a niche consultancy group with specialization in Private, Commercial and Retail Banking. Founded in 1999, SOFGEN's has 20 offices in 4 continents with strong presence in Asia Pacific, Latin America and Africa. 

The portfolio of service offerings are Multi‐Jurisdictional Tax Reporting, Liquidity Risk Analysis, Microfinance and additional core banking platforms." "SOFGEN has 450+ employees with 20+ Tier 1 client relationships. Delivering solutions “in and around” core banking the company has the 2nd largest pool of Avaloq consultants (Wealth Management Product) and is Temenos’ (Core Banking Software) most prolific partner.

 TechM will acquire SOFGEN for sub‐$30mn (1/3rd as earn‐outs paid over next 2 years depending on Revenue and Margin growth) in all cash deal and it will add revenue of $45mn with EBITDA margin of 8‐9% to TechM’s P&L." "We see this acquisition would strengthen presence of TechM in BFSI with new clients’ relationship.

 Moreover, new logos addition would provide cross selling opportunities. We retain our BUY rating with target price of Rs 3,050", says Prabhudas Lilladher research report.

Accumulate Asian Paints; target of Rs 747: P Lilladher

"APNT is one of the biggest beneficiaries of low crude prices as crude linked raw materials (including packaging) are 57% of input costs. We expect strong margin expansion for the coming couple of quarters, however extrapolating the same to FY17 looks too premature, given uncertainty regarding global crude oil prices. APNT had cut prices by 10% in 2009 and margin expansion in that cycle was led by excise duty reduction and acceleration in volume growth. We expect price cuts to materialise from 4QFY15.

 Our sensitivity analysis suggests that there is high probability of 40% EPS growth in FY16 whereas FY17 growth would be lower than current estimates due to higher margin in base quarter. We would wait for management commentary on product pricing and trend in crude oil prices before changing our estimates. We believe APNT is in a sweet spot due to huge growth opportunity in decorative paints given strong brand, distribution and innovations. 

We currently estimate 24% PAT CAGR over FY14‐17 and 21% PAT CAGR over FY15‐17. Retain Accumulate with a target price of Rs 747", says Prabhudas Lilladher research report.

Buy Infosys; target of Rs 2260: Kotak Securities

"Volume growth of 4.2% in a seasonally weak quarter was a surprise. Margins beat estimates but largely due to lower provisioning on doubtful debts. On important parameters, the annualized attrition rate has eased to 21.5% in 3Q v/s 25% in 2Q. Client penetration has also improved QoQ and 3 large deals have been signed. On newer initiatives, 9000 employees have been already trained on Design Thinking and 1000 developers on Machine Training. 

We believe that, these initiatives will shore up the growth rates of Infosys and sustain margins over the longer term, while having some impact on profitability in the short term. Guidance in CC terms has been maintained, we understand. With the developed economies growing / stabilizing, we do expect the demand scenario to improve over the next few quarters. 

Our FY16E EPS stands at Rs.122 (Rs.121) and TP at Rs.2260 (Rs.2239). ACCUMULATE (Buy at Declines)." We have been positive on the long-term demand prospects for quite some time. With the developed economies (especially US) stabilizing, we do expect the demand scenario to improve over the next few quarters. The margins for Infosys seem to be improving ahead of our expectations. 

The new strategy should allow Infosys to improve growth rates over the long term with sustained margins. "Our TP stands at Rs 2260. We recommend buying the stock at declines. ACCUMULATE", says Kotak Securities research report.

Buy Century Textiles; target Rs 560: Pritesh Mehta

Pritesh Mehta, Senior Technical Analyst at IIFL told CNBC-TV18, " Century Textiles and Industries  is ideal candidate for trend reversal because it has taken support at around Rs 500, following a sharp correction after making peak of Rs 594 in the third week of November.

This counter is on the verge of breaking out from an inverted head and shoulder pattern, also we can see an appearance of morning doji star candlestick. It tells us that the selling pressure has exhausted, the stock is on the verge of beginning a new up move altogether. So buy for a target of Rs 560," he added.

Accumulate SBI on any decline, says Mayuresh Joshi

Mayuresh Joshi of Angel Broking told CNBC-TV18, " State Bank of India  subsidiaries are probably responding to the news of a probable merger happening with State Bank of India. However, one really needs to see when and what price and how the whole thing happens. In my view probably State Bank of India is a much better bet within the PSU space." "The way we are looking at the NII growth for State Bank of India is going to be much better. Again from quarter earnings perspective the asset quality pressures would definitely ease on for bankers like State Bank. 

The management is probably doing the right moves. Again I think BFS portfolio is something that will lead the public sector banks in a big way. So, the treasury income is going to be substantial not just for State Bank of India but for most public sector banks," he added. "I think in terms of capital adequacy the bank is adequately sufficed to probably carrying on its balance sheet growth which means the operating leverage benefits would stay with State Bank.

 So, I would prefer investors with a long term view to probably stay with State Bank and probably accumulate the stock on any significant decline that one probably sees," he said.

Buy NRB Bearings; target of Rs 165: ICICIdirect

NRB Bearings (NRB) is the leader in the needle roller bearings segment in India with ~70% market share. With customised offerings and a pure play on the mobility segment, NRB enjoys a sticky clientele across all leading OEMs coupled with a strong exports segment (forming ~23% of FY14 topline) that has grown at 25.7% CAGR in FY09-14. With automotive volumes showing early signs of recovery coupled with a strong launch pipeline and product refreshes ahead, we expect the consolidated topline and earnings to grow at 17.4% and 39.3% CAGR, respectively, in FY14-17E. We are initiating coverage on the stock with a BUY recommendation and an SoTP target price of Rs 165/share.

Leader in needle bearing segment NRB is the leader in the needle bearing segment in India with ~70% market share. Needle roller bearings constituted ~55% of NRB’s topline in FY14. A needle roller bearing, as a customised product, requires NRB to work with OEMs from the conceptualisation stage. This enables it to build sticky clientele relationships with almost all major OEM players.

 Apart from needle bearings, cylindrical bearings are the other key product with needle and cylindrical bearings together forming ~68% of the topline. Early signs of auto revival + strong launch pipeline augur well for NRB For YTDFY15, auto volumes have recovered with 11.6% growth (mainly driven by two-wheeler segment growth, which was up 13.7% YoY). With the auto industry finally showing signs of a recovery after nearly two years of a demand slump coupled with a strong launch pipeline and product refreshes, we expect bearings demand from the OEM segment to pick up significantly. Therefore, net revenues from the OEM segment are expected to grow at 15% CAGR during FY14-17E to Rs 560 crore. De-risked geographical presence through strong exports… 

To expand its geographical footprints and foray into newer platforms, NRB has forayed into exports wherein it caters to global players such as Daimler, Renault, Volvo and Getrag. NRB’s exports, which grew at 25.7% CAGR over FY09-14, have also provided a natural hedge for its import of raw materials. Exports, which formed ~7.6% of the topline in FY10, now constitute ~23.3% of revenues in FY14. We expect NRB’s export revenues to grow at 23.3% CAGR in FY14-17E to Rs 260 crore in FY17E. Strong earnings growth to boost valuations… "Given NRB’s leadership position in the needle roller bearings space with a pure play in the mobility segment recovery and strong consolidated earnings growth at 39.3% CAGR in FY14-17E, we initiate coverage on NRB with a BUY rating. We ascribe a multiple of 18x (at ~30% discount to SKF) on the FY17E earnings to arrive at a valuation of Rs 165/share", says ICICIdirect.com research report.

Buy Tata Steel for long term, says Neeraj Deewan

Neeraj Deewan, Quantum Securities told CNBC-TV18, “I would not really buy metals right now because I need to get lot more clarity regarding the demand, raw material prices and raw material availability. So, it can be a trading bet once they fall like  Tata Steel  fell a lot.”

 “If someone has a very long term perspective may be he can start buying the stocks like Tata Steel which is still very close to the 52-week low. However in 6 months to one year there are a lot of other sectors which can outperform. So, this will come quite low under the sector specific investment that we are recommending,” Deewan added.

Buy ITC, Godfrey Phillips valuations attractive: Quantum

Neeraj Deewan, Quantum Securities told CNBC-TV18, “There is some buying in  Hindustan Unilever (HUL) which is happening because of this flight to safety. However I will not recommend people to go for FMCG stocks because they are not cheap.” 

“Definitely one is stock specific, one might get some opportunity here and there where the valuations are still attractive but as a pack whether it is HUL or whether it is  Godrej Consumer or others, I think they are very expensive. However,  ITC  I will put in different basket. We have buy rating, we have a coverage on a stock  Godfrey Phillips is valuationwise attractive. So, may be certain pockets will be there where valuation is there but generalised if you see FMCG I think valuations are very rich right now,” he said.

Buy Infosys; target of Rs 2400: ICICI

Rahul Mohindar, viratechindia.com told CNBC-TV18, “ Hindustan Unilever  (HUL) can do it more. But would I buy it at this point or recommend buying it at this point? I think the risk to reward ratio doesn’t justify it. We have seen quite a large run up and I think at this point in time may be 3-4 percent more is there on the stock before a nice big correction.” 

“So, I would refrain from buying in and probably use the next bout of a run up, the next 3-5 percent to take off some profits,” he added.

Accumulate Infosys; target of Rs 2285: Dolat Capital

Volume grew by 4.2% QoQ, best in last 12 quarters. The company expects strong volume momentum to continue despite the mixed view on client’s budgets trends. Company has maintained guidance of 7-9% $ revenue growth at Q2 exchange rates, implying -1% to 6% QoQ growth for Q4, further adding suspense on trend forward. It has added 59 new clients (gross) in the quarter and expects trends to better both on discretionary, non-discretionary and digital across verticals except for Telecom, select Energy/manufacturing clients.

 No concern on Productivity going forward despite the weak realization trend in recent past as it is witnessing uptick in pockets and would spread across verticals. Not expecting any specific concerns in any of the geography in particular. "We believe CEO Dr Sikka has helped in loads of confidence restoration through its commentary on its positive interactions with all stakeholders, 100% variable payout for entire workforce in Q3, sustained deal traction and endeavor to regain its bellwether tag in the industry through leading new technology and strong financial outperformance.

We believe the strong volume growth (4.2% QQ), better commentary outlook, broad basing of growth and improved OPM profile at about 26% would help Infosys in its efforts on confidence restoration and would mean sustained marketperformance as long as it keep on delivering in line with its aspiration on improved volume (15%+) and profitability (26%+).

 We have broadly maintained our estimates with a Revenue/earnings CAGR of 13%/14% over FY15-17E. We maintain our rating ofMarket-performer on the stock with a TP of Rs 2285 valued at 16x on FY17E earnings (inline with current discounting). Accumulate the stock for target price of Rs 2285", says Dolat Capital research report.

Buy Jaiprakash Associates: Manas Jaiswal

Manas Jaiswal of manasjaiswal.com told CNBC-TV18, " Jaiprakash Associates   is making higher tops and higher bottoms from the level of Rs 23. The stock can test 50-day moving average which is placed at Rs 29. 

So even at current level one can buy JP Associates with a stoploss at Rs 25.75." On Thursday, Jaiprakash Associates closed at Rs 26.75, up Rs 1.30, or 5.11 percent. It has touched an intraday high of Rs 27.10 and an intraday low of Rs 25.85.

Buy Motherson Sumi; target of Rs 590: ICICIdirect.com

Technical Outlook The share price of Motherson Sumi Systems has registered a breakout from the bullish Cup and Handle pattern on Wednesday signalling the end of the secondary consolidation and resumption of the next up leg, thereby offering a fresh entry opportunity to ride the ongoing uptrend from a medium-term perspective. 

The earlier share price retraced its three week decline (Rs 450-394) in just a week indicating a positive price structure as rallies are stronger and faster whereas corrections are shallow and time consuming. The 21 week EMA has historically acted as a strong support in the stock during the secondary corrective price action as can be seen in the adjacent chart and is currently placed at Rs 404. The stock has seen a strong pullback from the support level and has rallied from strength to strength, thereafter. 

It has consistently made higher peaks and bottoms, which indicate a strong appetite to own the stock among market participants. Volume behaviour also supports the overall bullish stance as rallies throughout the year have been on the back of volumes double the 50-week average of 45 lakh shares per week while the secondary correction have seen relatively low volume participation. Considering the overall positive price structure, we believe the stock offers a good reward/risk set-up to ride the next up move. We expect the stock to head towards Rs 590 in the medium-term being the 123.6% extension of the previous major rally (Rs 257 to Rs 448) as measured from the October 2014 low of Rs 352. 

Fundamental Outlook Motherson Sumi (MSL) has been increasing its presence across multiple product segments and customers either by forming joint ventures for different product lines or by cross-selling product or technologies. The company has been able to acquire companies available at distressed valuations with assured business from OEMs. The standalone business has also benefited from this and MSSL has grown faster than the domestic auto industry by increasing content per car as its association with the overseas subsidiaries continues to help garner more business in India from global OEMs. 

With MSL’s competence on turning around businesses evident from the success of SMR and SMP, we believe the management’s strong focus on RoCE augurs well for the performance in the wake of strong growth potential. MSL’s performance has sustained (PAT CAGR has driven up valuations in sync). Our outlook on the business remains positive with strong growth likely from both organic and inorganic sources, which are likely to ensure that multiples premium remains vis-à-vis peers. 

We value the company on SOTP valuation. However, on an overall basis, it remains attractive at ~16x PE, 7x EV/EBITDA FY17E earnings. 

Strategy: "Buy Motherson Sumi Systems in the range of Rs 448–456 for a target price of Rs 590.00 with a stop loss below Rs 395.00 on a closing basis", says ICICIdirect.com research report.

Book profits in Jet Airways: Kunal Saraogi

Kunal Saraogi of Equityrush told CNBC-TV18, "The risk reward clearly does not favour a buy in  Jet Airways  . I think this is the time to book profits in Jet Airways. 

We have seen a vertical move and most of the positives are already in the price. It has got a major resistance at Rs 450, so I don’t expect the stock to outperform from here on. 

So, given the risk, given its volatility, it is best to take profits and stay away from the stock for a little while." At 14:23 hrs Jet Airways was quoting at Rs 446, up Rs 8.90, or 2.04 percent. It has touched a 52-week high of Rs 458.90.

Buy Asian Paints, Kotak Bank, UltraTech Cement: Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, " Asian Paints  is rallying after a minor correction and a trading range. It was in our buy list yesterday in the morning and again in the afternoon.

It is a very nice stock to own. We want to buy it not only as a BTST call but also to hold it for a few days. If the Nifty is crossing 8300, Asian Paints should be a big winner." " Kotak Mahindra Bank  is an outperformer. 

The charts say it is making new highs and new highs for a bluechip should be a buying opportunity," he said. " UltraTech Cement  is the best of the cement lot. The stock was in a large trading range. It is breaking out today. 

it is a trading call but it is also a stock where you want to build a position if you want to make a small investment somewhere in the market today."

Buy Gujarat Pipavav Port, OnMobile Global: Pankaj Jain

Pankaj Jain of Sunteck Wealthmax Capital told CNBC-TV18, "One can buy Gujarat Pipavav Port   with a stoploss of Rs 223 and a target of Rs 234." "One can also buy OnMobile Global   with a target of Rs 84 and a stoploss of Rs 78," he said.

Buy ICICI Bank, Kotak Bank: Sharmila Joshi

Sharmila Joshi of sharmilajoshi.com told CNBC-TV18, "As far as  ICICI Bank   is concerned, 
one should buy it. Either buy it or  Kotak Mahindra Bank . It is an ideal time to get into a private bank because a lot of things still will play out in the next couple of years once the interest rate cycle turns for banking as a sector."

 " Suzlon Energy  has been in the news because they want to sell off some of their holdings and bring down their debt levels but overall if you track the way the company has been performing over the last couple of years, I would not put my money in Suzlon Energy," he said. 

" Elder Pharma is a decent stock within the pharmaceutical space and pharmaceutical space again is a space that I would be positive on but very honestly may be Elder Pharma would not be the stock that I would buy within the midcap, I would look at a stock may be like Biocon  at current level or among the larger players the stocks like Lupin  or Sun Pharma ."